Pharma Business Pakistan

429 posts

Doctors & Pharma Industry – Part 2 of 2 – Asrar Qureshi’s Blog Post #1218

Asrar Qureshi’s Blog Post #1218 addresses the complex relationship between pharmaceutical companies and doctors, emphasizing the need for ethical conduct in Pakistan’s healthcare system. It outlines a Code of Conduct for both sectors, aiming to balance industry collaboration with patient welfare, maintaining professionalism while avoiding conflicts of interest.
Share
View Post
  • 5 min

Doctors & Pharma Industry – Part 1 of 2 – Asrar Qureshi’s Blog Post 1217

The blog post by Asrar Qureshi explores the complex relationship between pharmaceutical companies and doctors, emphasizing its dual nature of necessity and ethical risk. It advocates for transparency and independence in education, particularly in the context of Pakistan’s healthcare challenges. The post highlights both issues and contributions of this relationship in improving patient access to treatment.
Share
View Post
  • 6 min

Pharmaceutical Distribution Systems – A Strategic Opportunity – Asrar Qureshi’s Blog Post #1215

Asrar Qureshi’s blog post discusses the urgent need for modernizing pharmaceutical distribution in Pakistan, shifting from a traditional logistics model to a strategic healthcare framework. It emphasizes cold-chain capabilities and digital transformation to improve patient outcomes as the market evolves towards specialty medicines and biologics, urging collaboration among stakeholders.
Share
View Post
  • 5 min

Novartis Pharma Exits from Pakistan – Asrar Qureshi’s Blog Post 1183

Asrar Qureshi’s Blog Post 1183 discusses Novartis Pakistan’s transfer to International Investment II Limited (IIL), emphasizing its implications for the pharmaceutical sector. While the change aims to ensure supply continuity and local management agility, there are concerns about potential risks, including access to innovative medicines and workforce stability. The deal represents a significant shift in Pakistan’s pharmaceutical landscape.
Share
View Post
  • 5 min

Pharma Marketing by 2030 – Asrar Qureshi’s Blog Post #1148

Asrar Qureshi’s Blog Post #1148 outlines anticipated changes in pharmaceutical marketing by 2030, emphasizing a hybrid omnichannel approach and AI integration in sales. The role of Medical Affairs will grow, and compliance will become real-time. In Pakistan, increased digital engagement and regulatory improvements will shape marketing strategies, enhancing patient support programs.
Share
View Post
  • 4 min

Pharma Selling in Five Years – The Shape of Things to Come – Asrar Qureshi’s Blog Post #1147

Asrar Qureshi’s blog post discusses the future of pharmaceutical sales by 2030, highlighting the shift from traditional relationship-driven methods to AI-driven approaches. It predicts a reduction in sales reps, emphasizing targeted engagement and a hybrid selling model. The role of sales reps evolves into that of trusted consultants, leveraging real-time data for better interactions.
Share
View Post
  • 6 min

Strategy Meetings in Pharma Industry – Asrar Qureshi’s Blog Post #1126

Asrar Qureshi’s blog post critiques the repetitive nature of annual strategy retreats in the pharma industry, highlighting their ineffectiveness. He proposes transformative approaches, such as framing retreats around key questions, inviting diverse voices, and fostering cross-functional collaboration. The goal is to inspire genuine innovation and actionable strategies for future success.
Share
View Post
  • 5 min

Recent Drug Safety Alerts – Asrar Qureshi’s Blog Post #1125

Asrar Qureshi’s Blog Post 1125 discusses post-marketing surveillance and pharmacovigilance efforts in reporting adverse drug reactions. It highlights recent FDA warnings about cetirizine, scopolamine patches, and mRNA COVID-19 vaccines concerning severe side effects, urging that this information be treated as essential for discussions among healthcare professionals.
Share
View Post
  • 5 min

Why Pakistan’s Pharmaceutical Exports Lag Behind and How to Fix It– Asrar Qureshi’s Blog Post #1124

Pakistan’s pharmaceutical exports are notably low despite having a robust industry, with challenges including inadequate investment in facilities, lack of international certifications, inconsistent compliance with quality standards, and insufficient market intelligence. Strategic reforms, including regulatory improvements and investment in workforce development, are essential for enhancing exports and achieving global competitiveness.
Share
View Post
  • 6 min

Formation of PharmEx Pakistan – Too Late, Too Little? – Asrar Qureshi’s Blog Post #1123

The Ministry of Commerce in Pakistan is launching PharmEx Pakistan to boost pharmaceutical exports, aiming to increase annual exports from $700 million to $3 billion. This public-private initiative, modeled after India’s Pharmexcil, seeks to enhance regulatory compliance and global visibility for Pakistani pharmaceuticals, while facing challenges in international competitiveness.
Share